Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 8/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | IL1B | P01584 | 1/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | GRAMD1A | Q96CP6 | 2/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | PDE6D | O43924 | 5/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26149874 | 1.00 | DDB1 (0.56) | DDB1CRBNTNFIL1BIKZF3 | |
| SCHEMBL26147900 | 1.00 | DDB1 (0.56) | DDB1CRBNTNFIL1BIKZF3 | |
| SCHEMBL30275742 | 1.00 | DDB1 (0.56) | DDB1CRBNTNFIL1BIKZF3 | |
| SCHEMBL24459097 | 0.91 | CRBN (0.57) | DDB1CRBNTNFIL1BIKZF3 | |
| SCHEMBL29617067 | 0.91 | CRBN (0.57) | DDB1CRBNTNFIL1BIKZF3 | |
| SCHEMBL25342825 | 0.86 | CRBN (0.61) | DDB1CRBNTNFIL1BIKZF3 | |
| SCHEMBL24459215 | 0.84 | CRBN (0.64) | DDB1CRBNTNFIL1BIKZF3 | |
| SCHEMBL30862218 | 0.84 | CRBN (0.64) | DDB1CRBNTNFIL1BIKZF3 | |
| SCHEMBL24459129 | 0.84 | CRBN (0.64) | DDB1CRBNTNFIL1BIKZF3 | |
| SCHEMBL30241730 | 0.84 | CRBN (0.64) | DDB1CRBNTNFIL1BIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| EP-4132529-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | DDB1 987/4885CRBN 179/4885TNF 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.